Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | OT |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | UNK | — | OT |
received an extra dose of MENQUADFI instead of the intended MENB with no reported AE; received an extra dose of MENQUADFI instead of the intended MENB with no reported AE; Initial information received on 11-Feb-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 17 years old male patient who had received an extra dose of Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] instead of the intended MENB (Meningococcal Vaccine B) with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s),concomitant medications and family history were not provided. On 23-Oct-2018 he also received a dose 1 of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine (Solution for injection) with an unknown batch number via unknown route in unknown administration site, On 06-Feb-2024, the patient received a dose 2 of same vaccine lot number not reported via unknown route in unknown administration site. On 11-Feb-2025 he also received a dose 3 of 0.5 ml of vaccine U8351BA, Expiry date; 31-Mar-2028, strength was unknown via intramuscular route in the left deltoid for Immunization and received an extra dose of menquadfi instead of the intended menb with no reported adverse event (wrong product administered) and (extra dose administered) (latency: same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.